<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2000">
  <stage>Registered</stage>
  <submitdate>11/06/2008</submitdate>
  <approvaldate>11/06/2008</approvaldate>
  <nctid>NCT00696917</nctid>
  <trial_identification>
    <studytitle>Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix-B in Healthy Volunteers = 15y</studytitle>
    <scientifictitle>Safety and Immunogenicity of 3 Lots of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine, Administered According to a 2 Dose Schedule, and Engerix-B Administered According to a 3 Dose Schedule to Healthy Volunteers = 15 Years of Age</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>208129/031</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - HBV-MPL vaccine 208129
Other interventions - Engerix-B

Active Comparator: Group A - Three doses according to 0, 1, 6-month schedule

Experimental: Group B - Two doses according to 0, 6-month schedule, with a placebo injection at Month 1

Experimental: Group C - Two doses according to 0, 6-month schedule, with a placebo injection at Month 1

Experimental: Group D - Two doses according to 0, 6-month schedule, with a placebo injection at Month 1


Other interventions: HBV-MPL vaccine 208129
2-dose intramuscular injection 3 different vaccine lots

Other interventions: Engerix-B
3-dose intramuscular injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Occurrence, intensity and causal relationship of any (solicited/unsolicited adverse event) general symptoms</outcome>
      <timepoint>Full course of vaccination</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of serious adverse events</outcome>
      <timepoint>Study period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-HBs antibody concentrations</outcome>
      <timepoint>At Month 7</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence and intensity of solicited local signs and symptoms</outcome>
      <timepoint>4-day after vaccination</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence, intensity and relationship to vaccination of solicited general signs and symptoms</outcome>
      <timepoint>4-day after vaccination</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence, intensity and relationship to vaccination of unsolicited signs and symptoms</outcome>
      <timepoint>30 days after vaccination</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence and relationship to vaccination of SAEs</outcome>
      <timepoint>During the study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-HBs antibody concentrations</outcome>
      <timepoint>At Months 1, 2, 6 and 7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  A male or female aged = 15 years at the time of the first vaccination. In Centre 103
             (Germany) and Centre 1 (Netherlands), only subjects = 18 years will be enrolled.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Written informed consent obtained from the subject and/or from the parent or guardian
             of the subject.

          -  If the subject was a female, she was of non-childbearing potential, if of childbearing
             potential, she was abstinent or used adequate contraceptive precautions for one month
             prior to enrollment and up to two months after the last vaccination</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine (s) during the study period or within 30 days preceding the first dose of
             study vaccine.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             during the period starting from 30 days before each dose of vaccine and ending 30 days
             after.

          -  Previous vaccination against hepatitis B.

          -  History of non-response to previous hepatitis B vaccination.

          -  Known exposure to hepatitis B within the past 6 weeks.

          -  History of hepatitis B infection.

          -  Confirmed human immunodeficiency virus (HIV) infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Acute disease at the time of enrollment.

          -  Hepatomegaly, right upper quadrant abdominal pain or tenderness.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration/ administration
             during the study period.

          -  Pregnant or lactating female</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/1999</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1303</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>GSK Clinical Trials Call Center - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralové</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study was conducted to evaluate the lot-to-lot consistency of three lots of HBV-MPL
      vaccine and to compare their safety and immunogenicity with that of Engerix-B.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00696917</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>